Contribution of human recombinant Interferon-Alpha 2b treatment in symptomatic and asymptomatic patients with SARS-CoV-2 virus infection

Introduction: Subjects with asymptomatic infections are not generally admitted to health care facilities, however, they may benefit from antiviral therapy.Objective: To evaluate the contribution to treatment with combined therapy based on recombinant human interferon alpha 2b + Lopinavir/Ritonavir...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Revista Habanera de Ciencias Médicas
Päätekijät: Cristobal González-Losada, Anabel González Blanco, Luis Gabriel González-Lodeiro, Abraham Ismael Beato Canfux, Diana del-Barco-García, Gerardo Enrique Guillén Nieto
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Universidad de Ciencias Médicas de La Habana 2022
Aiheet:
Medicina
19
CoV
SARS
COVID
Heberon®
Linkit:https://www.redalyc.org/articulo.oa?id=180473699007
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia